Health

STAT+: Early results for Alterome’s KRAS drug for pancreas, lung and colon cancer arrive

Both are already offering compounded drugs and eyeing BPC-157 and TB-500, two of six unapproved peptides covered by a new HHS policy easing enforcement against compounding pharmacies, STAT’s Sarah Todd and Katie Palmer write.

✦ Extractive summary — built from the sources' own reporting•From 1 source•1 min read•Updated November 20, 2026, 2:01 PM UTC
Key points
  • Continue to STAT+ to read the full story….
  • Want to stay on top of the science and politics driving biotech today?
  • Sign up to get our biotech newsletter in your inbox.

Hims and Noom take peptides further into mainstream Hims & Hers and Noom are getting into the synthetic peptide business, bringing treatments marketed for muscle maintenance, intimacy, and longevity to a much larger audience — often with little evidence to support those uses.

How this summary was made: extractive summary — built from the sources' own reporting. It is drawn only from the reporting of the sources listed below — read the originals for full detail. How we summarize →

Advertisement

Every article behind this summary — 1 article from 1 outlet